Posts

OCT-A Biomarker Predicts Early Glaucoma Progression

By Dr. Kevin -
Image
A 4.9-year longitudinal study published in the American Journal of Ophthalmology suggests that microvasculature dropout (MvD) detected via OCT angiography (OCT-A) serves as a critical prognostic marker for patients with preperimetric glaucoma (optic nerve damage without initial visual field loss). Key Study Findings Faster Vascular Decline: Eyes with baseline MvD experienced a significantly faster reduction in circumpapillary capillary density compared to those without MvD ( -0.88% per year vs. -0.23% per year ). Higher Conversion Rates: Over an average follow-up of 6.8 years, 62.5% of eyes with baseline MvD progressed to perimetric glaucoma (measurable visual field loss), compared to just 26.2% of eyes without it—a 2.5-fold higher risk. Baseline Vulnerability: At the start of the study, the MvD group already exhibited lower capillary density (45.6% vs. 47.7%) and thinner retinal nerve fiber layers (RNFL) than the control group. Clinical Takeaways Because capillary density loss...
Post a Comment
Read more

Summary: High HDL-C Linked to Increased Dry AMD Risk

By Dr. Kevin -
Image
  A retrospective cohort study analyzed electronic healthcare data from 70 US facilities (2005–2025) to evaluate how high-density lipoprotein cholesterol (HDL-C) levels impact the risk of age-related macular degeneration (AMD). Key Findings Higher Dry AMD Risk: High HDL-C levels were associated with a significantly increased risk of incident nonexudative (dry) AMD across all stages compared to low levels. Weaker Wet AMD Link: The association with exudative (wet) AMD was present but weaker and less consistent. Risk Breakdown (Hazard Ratios): Overall Dry AMD:Early Atrophic Stage: HR = 1.55 Intermediate Atrophic Stage: HR = 1.82 Advanced Atrophic Stage: HR = 1.85 Overall Wet AMD: HR = 1.37 Study Design & Methodology Researchers matched 186,532 subjects into high and low HDL-C groups based on demographics, medications, and comorbidities. The risk estimates remained directionally consistent and stable even after adjusting for these variables. The authors concluded that future st...
Post a Comment
Read more

Bausch + Lomb Launches PreserVision AREDS3

By Dr. Kevin -
Image
 Bausch + Lomb has introduced PreserVision AREDS3 , an over-the-counter oral supplement designed to reduce the risk of disease progression in patients with age-related macular degeneration (AMD). Key Features & Formulation Core Nutrients: Contains the complete, National Eye Institute-recommended AREDS2 formula to protect macular health by neutralizing free radicals (vitamins C and E, lutein, zeaxanthin, zinc, and copper). New B-Vitamin Complex: Adds thiamin, riboflavin, niacin, pantothenic acid, vitamin B6, biotin, folate, and vitamin B12 to promote healthy cellular eye function. Enhanced Absorption: Offers approximately twice the nutrient absorption of previous AREDS formulations. Scientific Backing The inclusion of B vitamins is supported by over two decades of research across more than 20 human studies (including the Women’s Antioxidant and Folic Acid Cardiovascular Study ), which tie specific B-vitamin supplementation to a reduced risk of AMD. Bausch + Lomb plans to con...
Post a Comment
Read more

NSAID Use Linked to Lower AMD Risk

By Dr. Kevin -
Image
A retrospective cohort study published in Ophthalmology suggests that NSAIDs may reduce the risk of developing age-related macular degeneration (AMD) . Because inflammation plays a central role in both wet (exudative) and dry (non-exudative) AMD, researchers in Taiwan investigated whether the anti-inflammatory properties of these drugs offer a protective effect. Key Findings The study compared 634,794 patients prescribed NSAIDs against an equal number of non-users (both groups averaging roughly 60 years old) and found: Sustained Protection: NSAID users showed a reduced risk for AMD across all tracked time points, including at six months (HR: 0.31), one year (HR: 0.36), three years (HR: 0.42), and five years (HR: 0.48). Over the entire study duration, the overall hazard ratio was 0.58. Drug Types: The protective effect was observed both in patients prescribed aspirin (HR: 0.72) and those taking non-selective COX inhibitors other than aspirin (HR: 0.41). Subtypes & Comorbiditie...
Post a Comment
Read more

For GA Treatment, the Earlier the Better

By Dr. Kevin -
Image
A study from the ARVO 2026 meeting confirms that early intervention for geographic atrophy (GA) using pegcetacoplan (Syfovre) significantly improves long-term outcomes compared to delayed treatment. Key Study Findings Researchers analyzed 782 patients transitioning from the two-year OAKS/DERBY trials into the three-year GALE extension study. Superior Tissue Preservation: Patients who started treatment immediately (early group) preserved 3.87 mm² of retinal tissue over five years. Those who started two years late (delayed group) preserved only 1.93 mm² . Reduced Growth Rates: In nonsubfoveal GA, monthly injections reduced lesion growth by 33% compared to the sham group. Disease Delay: Continuous five-year therapy delayed the progression of nonsubfoveal GA by approximately 16.5 to 18.5 months . Safety Profile: The treatment remained well-tolerated over five years. Rare instances of retinal vasculitis occurred in fewer than 1 in 4,000 cases, consistent with earlier trial data. C...
Post a Comment
Read more

Bupropion May Benefit Patients with Diabetic Retinopathy

By Dr. Kevin -
Image
A study presented at the ARVO 2026 meeting suggests that bupropion (Wellbutrin) may slow the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. Researchers believe the drug’s ability to reduce systemic inflammatory cytokines contributes to these protective ocular effects. Key Study Results Using the Chang Gung Research Database in Taiwan, researchers compared 1,574 adults with preexisting DR. Patients taking bupropion showed significantly better outcomes than non-users: Complication Reduction: Bupropion users had a 6.9% incidence of major DR complications (like retinal detachment or vitreous hemorrhage) compared to 12.8% in the control group. Fewer Interventions: There was a substantial drop in the need for retinal lasers, vitrectomies, or intravitreal injections. Broad Ocular Benefits: The data also indicated a lower risk of developing cataracts and glaucoma , as well as a reduced need for intraocular pressure-lowering medications. Conclusion While t...
Post a Comment
Read more

GLP-1 USE ASSOCIATED WITH PROTECTION AGAINST GLAUCOMA, CME AND ESPECIALLY AMD.

By Dr. Kevin -
Image
  A retrospective cohort study presented at ARVO 2026 , which suggests that GLP-1 receptor agonists (such as semaglutide, tirzepatide, and liraglutide) may offer protective benefits for eye health in non-diabetic adults with a BMI of 27 or higher. Key Findings The study compared over 31,000 patients using these medications for weight loss against a matched group with no GLP-1 prescriptions. Over a four-year period, those on GLP-1 drugs showed a reduced risk for several major ocular conditions: Significant Reductions: The most robust protection was seen against Age-Related Macular Degeneration (AMD) , both dry and wet forms. Glaucoma Protection: Use was associated with a strong reduction in the risk of both primary open-angle and angle-closure glaucoma. Macular Health: There was a moderate decrease in the incidence of cystoid macular edema (CME). Surprising Results: Contrary to some previous studies, this data showed a slight reduction in the risk of NAION (non-arteritic isch...
Post a Comment
Read more